Dronedarone and Sodium Polystyrene Sulfonate Suspension
Determining the interaction of Dronedarone and Sodium Polystyrene Sulfonate Suspension and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using dronedarone together with sodium polystyrene sulfonate can increase the risk of an irregular heart rhythm that may be serious. If your doctor prescribes these medications together, you may need regular monitoring of your electrolyte (magnesium, potassium) levels as well as other tests to safely use both medications. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, or fast or pounding heartbeats during treatment with dronedarone. In addition, you should let your doctor know if you experience signs of electrolyte disturbance such as weakness, tiredness, drowsiness, confusion, muscle pain, cramps, dizziness, nausea, or vomiting. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR CLOSELY: Dronedarone may cause dose-related prolongation of the QT interval. Since hypokalemia and hypomagnesemia are known risk factors for arrhythmia associated with QT prolongation, coadministration of dronedarone with agents that can cause significant potassium and/or magnesium loss (e.g., potassium-wasting diuretics, amphotericin B, cation exchange resins) may increase the risk of ventricular arrhythmias such as torsade de pointes and sudden death.
MANAGEMENT: Caution is advised if dronedarone must be used concomitantly with medications that can cause significant potassium and/or magnesium loss. Serum electrolytes should be evaluated at baseline and at regular intervals throughout the duration of therapy. Any abnormalities should be corrected prior to initiating therapy, and levels should be maintained within the normal range during treatment. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope. Dronedarone should be discontinued if QTc Bazett interval increases to 500 ms or greater.
- "Product Information. Multaq (dronedarone)." sanofi-aventis , Bridgewater, NJ.
Generic Name: sodium polystyrene sulfonate
Brand name: Kalexate, Kayexalate, Kionex
Synonyms: Sodium polystyrene sulfonate, Sodium Polystyrene Sulfonate
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dronedarone-Sodium Sulf/Potassium Sulf/Mag Sulf/Polyethylene Glycol-Electrolyte Soln
- Dronedarone-Sodium Sulfacetamide and Sulfur Aqueous Gel
- Dronedarone-Sodium Sulfacetamide and Sulfur Cleanser
- Dronedarone-Sodium Sulfacetamide and Sulfur Cream
- Dronedarone-Sodium Sulfacetamide and Sulfur Foam
- Dronedarone-Sodium Sulfacetamide and Sulfur Lotion
- Sodium Polystyrene Sulfonate Suspension-Dronedarone Hydrochloride
- Sodium Polystyrene Sulfonate Suspension-Droperidol
- Sodium Polystyrene Sulfonate Suspension-Droperidol Injection
- Sodium Polystyrene Sulfonate Suspension-Drospirenone
- Sodium Polystyrene Sulfonate Suspension-Drospirenone and estradiol
- Sodium Polystyrene Sulfonate Suspension-Drospirenone and ethinyl estradiol